AtaiBeckley wins OVID Health Silver Award for patient partnership in psychedelic trials

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) said on Monday it had received the Silver Award in OVID Health's 2026 Patient Participant Index, recognizing its collaboration with the Psychedelic Participant Advocacy Network (PsyPAN) to strengthen participant involvement in psychedelic clinical research. The clinical-stage biotechnology company said the award highlights a multiyear partnership aimed at incorporating the lived experiences of clinical trial participants into the development of mental health treatments.